GlassScriptPhysician profile
Taylor Bailey Beck
NPI 1720601610
$1,611.86
in general payments reported to CMS, 2019-2025
29 companies · $392 in 2025
The $392 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.68 · 2022: $197 · 2023: $554 · 2024: $454 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,392 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,391.55 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $276.58 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Stryker Corporation | $168.57 | 2023 | Insignia, Mako, Triathlon |
| Lilly USA, LLC | $138.86 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $113.77 | 2023-2025 | Farxiga, Breztri, Lokelma |
| Abbvie INC. | $103.06 | 2023-2025 | |
| Pfizer INC. | $100.17 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $87.66 | 2021-2023 | |
| Amgen INC. | $86.73 | 2022-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.90 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $54.89 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $49.24 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $46.00 | 2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $28.75 | 2025 | Gemtesa |
| Mylan Specialty L.P. | $27.68 | 2024 | Yupelri |
| Daiichi Sankyo INC. | $23.63 | 2023 | Injectafer |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $22.50 | 2025 | Voquezna |
| Organon LLC | $17.59 | 2023 | Nexplanon |
| Astellas Pharma US INC | $17.26 | 2025 | Veozah |
| Medtronic, INC. | $17.14 | 2024 | Intellis Adaptivestim |
| Dynavax Technologies Corporation | $17.09 | 2024 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $16.77 | 2023 | Quviviq |
| Gilead Sciences, INC. | $16.56 | 2022 | |
| Exact Sciences Corporation | $16.37 | 2023 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $15.32 | 2023 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $15.08 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.42 | 2022 | |
| Merck Sharp & Dohme LLC | $13.23 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Lundbeck LLC | $12.62 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.